The FDA user fee agreements were signed into law earlier this year despite the Trump administration's expressed preference for a fully user fee-funded agency, but the new user fee agreements are all new programs, and hence the agency's ability to spend those monies could be hampered by the use of a new three-month continuing resolution to fund government operations.